


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:


LISTING OF CLAIMS:

1. (original) A process for the preparation of a compound of formula (II)




in which R is hydrogen, a protecting group or a salifying group and Y is a $-B(OR_4)_2$ group, wherein each R_4 is independently hydrogen or C_1 - C_6 alkyl; or a $-ZnX$ group, wherein X is a halogen atom selected from chlorine, bromine and iodine;

which comprises the reaction of a compound of formula (V)




wherein R is as defined above and R_2 and R_3 , which can be the same or different, are straight or branched C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, trialkylsilyl, or R_2 and R_3 , taken together with the nitrogen atom they are linked to, form a saturated, optionally substituted, heterocyclic ring, containing one to two further heteroatoms independently selected from nitrogen, oxygen and sulfur;

either with a compound of formula (VI)



wherein X is as defined above;


or with a compound of formula (VIa)



wherein each R'_4 is independently $\text{C}_1\text{-C}_6$ alkyl,

and, if desired, the subsequent hydrolysis of the resulting boranic ester of formula (II).


2. (original) A process as claimed in claim 1, in which the stoichiometric ratio of a compound of formula (VI) or (VIa) to a compound of formula (V) ranges from 1.0 to 5.0.
3. (original) A process as claimed in claim 2, in which the stoichiometric ratio of a compound of formula (VI) or (VIa) to a compound of formula (V) ranges from 1.1 to 3.0.
4. (currently amended) A process as claimed in claim 1 ~~or 2~~, in which the reaction is carried out in an ether solvent or mixtures thereof with an apolar solvent, at a temperature ranging from 20°C to the reflux temperature.
5. (original) A process as claimed in claim 1, in which a compound of formula (V) is prepared by reaction between a compound of formula (III)



(III)

wherein R is as defined in claim 1,


with a compound of formula (VII)



wherein R_2 and R_3 are as defined in claim 1.


6. (original) A process as claimed in claim 5, in which the stoichiometric ratio of a compound of formula (VII) to a compound of formula (III) ranges from 0.5 to 3.0.
7. (original) A process as claimed in claim 6, in which the stoichiometric ratio of a compound of formula (VII) to a compound of formula (III) ranges from 1.0 to 2.0.
8. (original) A compound of formula (II), as defined in claim 1, wherein R is a 1-methyl-1-phenyl-ethyl group and Y is a $\text{-B}(\text{OR}_4)_2$ group, in which R_4 is as defined in claim 1.
9. (original) A compound as defined in claim 8, wherein each R_4 is independently hydrogen, methyl, ethyl or isopropyl.
10. (original) A compound as defined in claim 8, which is:

- 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenylboronic acid;
 - 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenylboronic acid methyl ester; or
 - 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenylboronic acid isopropyl ester.
11. (original) A compound of formula (V)



wherein R, R₂ and R₃ are as defined in claim 1.

12. (original) A compound as defined in claim 11, which is:
- 2-[2-t-butyl-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide;
 - 2-[2-sodium-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide; or
 - 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide.
13. (currently amended) The use of a compound of formula (V), as defined in claim 11 or 12, for the preparation of a compound of formula (I)




in which Z is an optionally substituted heterocycle containing at least one nitrogen atom; or an amido residue;
or of a pharmaceutically acceptable salt thereof.

14. (original) The use as claimed in claim 13, wherein in the compound of formula (I) the residue Z is selected from:

- 2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl;
- 2-ethoxy-7-carboxy-1H-benzimidazol-1-yl;
- 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-on-3-yl and
- (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoylamino.

15. (new) A process as claimed in claim 2, in which the reaction is carried out in an ether solvent or mixtures thereof with an apolar solvent, at a temperature ranging from 20°C to the reflux temperature.

16. (new) The use of a compound of formula (V), as defined in claim 12, for the preparation of a compound of formula (I)



in which Z is an optionally substituted heterocycle containing at least one nitrogen atom; or
an amido residue;
or of a pharmaceutically acceptable salt thereof.